Product Details
| Product Name:
Ixekizumab |
CAS No.:
1143503-69-8 |
| Purity:
95.4% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2024/11/15 |
Product Introduction
Bioactivity
| 名稱 | Ixekizumab |
| 描述 | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis. |
| 體外活性 | Ixekizumab (0.1-10000 pM) dose-dependently inhibits the secretion of growth-regulated oncogene (GRO)α induced by human IL-17A or human IL-17A/F heterodimers from HT-29 cells. Similarly, Ixekizumab demonstrates dose-dependent inhibition of GROα secretion from HT-29 cells induced by cynomolgus monkey IL-17A.[1]
The equilibrium KD values of Ixekizumab for IL-17A in humans and cynomolgus monkeys were 1.8 pM and 0.8 pM, respectively. Ixekizumab exhibited binding to rabbit IL-17A as well, although with a lower affinity and heterogeneous binding (with KD values of 1.3 nM and 14 nM, respectively). Notably, Ixekizumab did not demonstrate any binding to IL-17A in either mice or rats.[1] |
| 體內活性 | Ixekizumab (0.001-1 mg/kg; i.v.; C57BL/6 mice) exhibits a dose-dependent reduction in the secretion of keratinocyte chemoattractant (KC) induced by human IL-17A in the plasma of C57BL/6 mice. In male cynomolgus monkeys, intravenous (IV) administration of 1 mg/kg results in a mean elimination half-life of 6.5 days. Subcutaneous (SC) administration of 1 mg/kg yields a maximum plasma concentration of approximately 11.1 μg/mL around 72 hours post-dose, with a mean elimination half-life of about 10.3 days.[1] |
| 存儲條件 | store at low temperature | store at -20°C | Shipping with blue ice. |
| 關鍵字 | LY-2439821 | LY 2439821 | Ixekizumab |
| 相關產品 | Inosine pranobex | Apilimod mesylate | Amlexanox | Dexamethasone acetate | Bornyl acetate | L-Arginine | Bergenin | Dexamethasone | α-Terpineol | Diallyl disulfide | Linalool | Apilimod |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:16898-88-7
$31.00 / 5mg
-
CAS:1229208-44-9
$32.00 / 1mg
-
CAS:1474034-05-3
$38.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States